Accessibility Menu
Strata Skin Sciences logo

Strata Skin Sciences(NASDAQ) SSKN

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-100%
1 Year-100%
1 Month-96%
N/A
Strata Skin Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.012026-07-29
Strata Skin Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+2,650%USD 0.002026-07-22
1 month-95.8%USD 0.132026-06-29
3 month-96.1%USD 0.142026-04-30
Year to date-99.56%USD 1.262025-12-31
1 year-99.71%USD 1.892025-07-29
3 year-99.94%USD 9.502023-07-28
5 year-99.96%USD 14.302021-07-30
Since inception-100%USD 3,855.002005-10-28

Strata Skin Sciences Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$30.70M

Net Income (TTM)

-$6.49M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 19, 2026

SSKN News

Foolcom-Featured.png

Strata Skin Sciences Sales Decline

Motley Fool Markets TeamAug 13, 2025
featured-earnings-leadership-highlights.png

STRATA Skin Sciences Eyes Market Growth

Motley Fool Markets TeamAug 13, 2025

Buy, Sell, or Hold: MELA Sciences

Selena MaranjianMay 31, 2012

Here's What George Soros Has Been Buying and Selling

Selena MaranjianFeb 17, 2012

This Just In: More Upgrades and Downgrades

Rich SmithNov 9, 2011

FDA Approves! Investors Shrug.

Brian Orelli, PhDNov 3, 2011

3 Stocks Shaking the Market

Rich DupreyOct 18, 2011

Whoa! What Just Happened to My Stock?

Rich DupreyOct 6, 2011
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Strata Skin Sciences

STRATA Skin Sciences makes medical devices for treating skin conditions like psoriasis and acne. Its main products help doctors offer targeted light-based treatments in clinics. These devices aim to improve patient comfort and treatment results for common skin problems.

Gadgets for Good Skin: Products and Services

  • XTRAC Excimer Laser: Delivers targeted ultraviolet light for psoriasis and vitiligo; 70% of 2025 revenue.
  • VTRAC Lamp Systems: Provides broad ultraviolet light for skin conditions; mainly sold internationally.
  • TheraClear X Acne Therapy: Uses light and suction for mild to moderate acne; limited insurance coverage.
  • Dermatology Procedures Equipment: Sells devices and equipment; 30% of 2025 revenue.
  • Service and Support: Maintains and services devices for clinics and hospitals.

Growth Moves: Expansion and Strategy

  • Launched TheraClear X Acne Therapy in 2022 to expand product line.
  • Transitioned to direct distribution in Korea in 2019, Japan in 2020, China in 2021, and India in 2023.
  • Settled with Theravant Corporation in 2025, changing royalty terms for TheraClear X.
  • Entered into a new Carlsbad, CA manufacturing lease in March 2024; headquarters to shift to remote model after 2026.
  • Exited Pharos laser product by 2024 and had discontinued MelaFind business in 2016 to focus on core devices.

Why STRATA Stands Out (Without Showing Off)

STRATA uses a recurring revenue model, placing devices in clinics and charging per use. Its XTRAC system is widely covered by U.S. insurance, making treatments accessible for many patients. The company has a global footprint, with direct sales and distribution in key international markets.

Five Things You Need to Know

  • 2025 net revenue was $30.7 million, down 9% from 2024.
  • Dermatology Recurring Procedures made up 70% of 2025 revenue, up from 63% in 2024.
  • International sales were $10.1 million in 2025, 33% of total revenue, down 20% year-over-year.
  • Operating loss improved to $(4.7) million in 2025, from $(9.3) million in 2024.
  • Cash and cash equivalents were $7.9 million as of December 31, 2025.

Bottom Line

STRATA has shifted focus to recurring revenue and core devices, adapting to market and regulatory changes. The company faces financial challenges but continues to serve a global network of clinics treating common skin conditions.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

114

CEO

Dolev Rafaeli, PhD, MBA

Website

www.strataskinsciences.com

Headquarters

Horsham, PA 19044, US

SSKN Financials

Key Financial Metrics (TTM)

Gross Margin

57.83%

Operating Margin

-19.74%

Net Income Margin

-21.13%

Return on Equity

-360.33%

Return on Capital

-30.43%

Return on Assets

-21.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$17.75M

Operating Income

-$6.06M

EBITDA

-$564.00K

Operating Cash Flow

-$2.79M

Capital Expenditure

-$1.47M

Free Cash Flow

-$4.26M

Cash & ST Invst.

$7.91M

Total Debt

$16.27M

Strata Skin Sciences Performance Analysis

Strata Skin Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 36,161,00020.6%
20232023-12-31USD 33,358,000-7.8%
20242024-12-31USD 33,562,0000.6%
20252025-12-31USD 30,696,000-8.5%
Strata Skin Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-28.9%
Q22025-06-3012.5%
Q32025-09-30-9.6%
Q42025-12-3134.1%
Strata Skin Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.60101.2%
20232023-12-31USD -3.1094.0%
20242024-12-31USD -2.65-14.6%
20252025-12-31USD -1.35-49.2%
Strata Skin Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3151.4%
Q22025-06-30-929.2%
Q32025-09-3040.0%
Q42025-12-31102.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$9.29M

-3.0%

Gross Profit

$5.61M

-2.5%

Gross Margin

60.42%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

114

N/A

Net Income

$58.00K

+101.3%

EBITDA

$943.00K

+133.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$7.91M

+9.0%

Total Debt

$16.27M

-1.0%

Accounts Receivable

$4.12M

-21.5%

Inventory

$2.81M

+25.3%

Long Term Debt

$1.38M

-91.5%

Short Term Debt

$15.58M

+4650.0%

Return on Assets

-21.25%

N/A

Return on Invested Capital

-1.60%

N/A

Free Cash Flow

-$551.00K

-376.9%

Operating Cash Flow

-$239.00K

-134.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HSCSHeartSciences Inc.
$2.10-2.78%
PAVMPAVmed Inc.
$5.01-1.76%
BMRABiomerica, Inc.
$1.57-1.26%
GBSGBS Inc.
$0.47-1.58%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.44+0.13%
NOKNokia
$9.02+0.07%
MSFTMicrosoft
$455.32+0.17%
NVDANvidia
$193.85+0.02%

Questions About SSKN

What is the current price of Strata Skin Sciences?

Strata Skin Sciences is trading at N/A per share.

What is the 52-week range for Strata Skin Sciences?

Over the past 52 weeks, Strata Skin Sciences has traded between N/A and N/A.

How much debt does Strata Skin Sciences have?

As of the most recent reporting period, Strata Skin Sciences reported total debt of $16.27M.

How much cash does Strata Skin Sciences have on hand?

Strata Skin Sciences reported $7.91M in cash and cash equivalents in its most recent financial results.

What is Strata Skin Sciences’s dividend yield?

Strata Skin Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services